logo
Trump Rips Jerome Powell as Feud Shows No Sign of Cooling Down

Trump Rips Jerome Powell as Feud Shows No Sign of Cooling Down

Yahoo11-07-2025
President Trump on Friday morning threw barbs at Trump-appointed Federal Reserve Chairman Jerome Powell, against whom he's railed over and over again in recent months due to the Fed's refusal to cut interest rates.
The central bank's decision not to do so, however, seems to rest ultimately at the feet of Trump's economic mismanagement, as Powell said earlier this month that the Fed would have lowered rates this year were it not for Trump's tariffs.
But as TNR's Timothy Noah observes, Trump interprets Powell's judgment as evidence that he 'wants him to fail, because Trump is incapable of not taking anything personally.' As a result, the Fed chair has of late been on the receiving end of innumerable schoolyard insults from the president: 'numbskull,' 'dumb guy,' 'major loser,' 'low IQ,' 'Trump hater,' and so on.
'I think he's doing a terrible job,' Trump told reporters on Friday, though he said he wouldn't oust Powell. 'I think we should be three points lower interest rate. He's costing our country a lot of money. We should be number one, and we're not, and that's because of Jerome Powell.'
The president was quick to clarify that the United States is 'number one in the world,' just not 'in terms of interest,' before going on to credit himself for the country's purported transformation from a 'dead country' to 'the hottest country' (a new favorite adjective of his).
'I'll tell you a little simple—a little simple language,' Trump said. 'One year ago, our country was a dead country. We were going nowhere except down. We were the laughingstock all over the world. And now we're the hottest country anywhere in the world. We're number one everywhere, anywhere in the world. And that's all they're talking about, is our country.'
In reality, America's image in the eyes of the world has, per the Pew Research Center, declined during Trump's presidency. The U.S. is being seen as an increasingly unserious and unstable country on the international stage. And, as with Trump's gripes with Powell, this undoubtedly owes in no small part to the president's chaotic approach to trade policy and erratic leadership more broadly.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop
Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop

Yahoo

time22 minutes ago

  • Yahoo

Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop

Key Takeaways Novo Nordisk's U.S.-listed shares were slightly higher in recent trading after shedding a third of their value last week, when the company cut its full-year outlook and named a new CEO. The shares had resumed their steep downtrend last week on above-average volume, indicating selling conviction from larger market participants. Investors should watch major support levels on Novo Nordisk's chart around $36 and $29, while also monitoring key overhead areas near $60 and $ Nordisk's (NVO) U.S.-listed shares were up about 2% in recent trading after shedding about a third of their value last week, when the company cut its full-year outlook and named a new CEO, leading Wall Street analysts to downgrade the stock. Since hitting a record high in June last year, Novo Nordisk shares have lost roughly two-thirds of their value, pressured by increasing competition from rival Eli Lilly's (LLY) weight-loss drugs and challenges during trials of the company's next-generation obesity drugs. Below, we take a closer look at Novo Nordisk's weekly chart and use technical analysis to identify major price levels that investors will likely be watching after last week's dramatic sell-off. An Extended Downtrend With last week's drop, Novo Nordisk shares resumed their steep downtrend on above-average trading volume, indicating selling conviction from larger market participants. The sell-off coincided with the relative strength index (RSI) falling to its lowest levels since early May, signaling weakening price momentum, though the indicator neared its oversold threshold, increasing the chances for short-term bounces. It's also worth noting that the 50-week moving average continues to converge toward the 200-week MA, potentially setting the stage for an ominous death cross, a bearish pattern that forecasts lower prices. Let's identify two major support levels on Novo Nordisk's chart worth watching if selling resumes this week and also point out several key overhead areas to monitor during potential recovery efforts. Major Support Levels Worth Watching The first major lower level to watch sits around $36. This area would likely provide support near the upper range of a consolidation period that formed on the chart between October 2020 and April 2021. A more significant move lower could see the shares test lower support at the $29 level. Investors may look for buying opportunities in this area near a horizontal line that connects a range of corresponding price action on the chart between January 2018 and April 2020. Key Overhead Areas to Monitor An initial recovery effort could see the shares climb to overhead resistance around $60. The price may encounter selling pressure in this area near the prominent April trough and April 2022 peak. A more bullish upswing opens the door for a rally toward $78. Investors who have bought Novo Nordisk shares at lower levels may decide to lock in profits in this location near the June peak, which closely aligns with the completion of a pullback in July 2023. The comments, opinions, and analyses expressed on Investopedia are for informational purposes only. Read our warranty and liability disclaimer for more info. As of the date this article was written, the author does not own any of the above securities. Read the original article on Investopedia Sign in to access your portfolio

NCAA Tournament fields to remain at 68 teams in 2026, but future growth is possible
NCAA Tournament fields to remain at 68 teams in 2026, but future growth is possible

Yahoo

time22 minutes ago

  • Yahoo

NCAA Tournament fields to remain at 68 teams in 2026, but future growth is possible

The NCAA men's and women's basketball tournaments will not expand beyond 68 teams in 2026, but future growth remains on the radar. 'Expanding the tournament fields is no longer being contemplated for the 2026 men's and women's basketball championships," Dan Gavitt, NCAA senior vice president of basketball, said in a statement on Monday. "However, the committees will continue conversations on whether to recommend expanding to 72 or 76 teams in advance of the 2027 championships.' NCAA President Charlie Baker has said adding teams could add value to the tournament, and he said the NCAA already has had 'good conversations' with TV partners CBS and Warner Bros., whose deal runs through 2032 at the cost of around $1.1 billion a year. ___ AP college basketball: and

RGTI: Rigetti Shares Jump after Needham hikes target on U.S. quantum momentum
RGTI: Rigetti Shares Jump after Needham hikes target on U.S. quantum momentum

Yahoo

time22 minutes ago

  • Yahoo

RGTI: Rigetti Shares Jump after Needham hikes target on U.S. quantum momentum

Aug 4 - Rigetti Computing (NASDAQ:RGTI) jumped more than 5% on Monday shortly after Needham raised its price target by $3, signaling fresh momentum in quantum computing. Warning! GuruFocus has detected 3 Warning Signs with RGTI. Analyst Quinn Bolton sees growing buzz around federal programs like DARPA's Quantum Benchmark Initiative (QBI) and the proposed Department of Energy Quantum Leadership Act. He believes those efforts could unlock new research funding and commercial opportunities. Rigetti leads a pack of startups racing to prove quantum machines can outperform classical systems. QBI aims to assess whether quantum devices deliver more value than their cost by 2033. Meanwhile, the DOE bill would allocate $2.5 billion over five years to boost quantum research. Investors weigh the promise of those programs against current realities: most quantum firms still run R&D losses and generate modest revenue. Bolton urges a cautious stance, recommending smaller, speculative positions. Yet his buy rating on Rigetti reflects confidence that government backing could pave the way for breakthroughs and higher stock gains. With Washington pulling out all the stops to keep the U.S. on the leading edge of high-tech, Rigetti advocacy demonstrates the crossroad of policy and private money. This is the place to keep an eye on future legislative actions and DARPA milestones to get new startup catalysts. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store